Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Agile Therapeutics, Inc. - Common Stock (NQ:AGRX)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Agile Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Agile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act’s No-Cost Contraceptive Coverage Requirement
From Agile Therapeutics, Inc.
Via GlobeNewswire
News headline image
Agile Therapeutics Posts Growth In Third Quarter Results, Reiterates Confidence In Target of $25M Net Revenue, Positive Cash Flow In 2024
Via ACCESSWIRE
News headline image
Agile Therapeutics Posts Growth In Third Quarter Results, Reiterates Confidence In Target of $25M Net Revenue, Positive Cash Flow In 2024 ↗
Agile Therapeutics, Inc. (NASDAQ: AGRX), the commercial-stage women’s healthcare company, posted a 122% increase in third-quarter revenue year-over-year, driven by strong demand for TwirlaⓇ... 
Via Benzinga
News headline image
Why Shares of Agile Therapeutics Jumped This Week ↗
The women's healthcare company got an analyst upgrade. 
Via The Motley Fool
News headline image
Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Agile Therapeutics, Inc.
Via GlobeNewswire
News headline image
Agile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023
From Agile Therapeutics, Inc.
Via GlobeNewswire
News headline image
A Look Into Healthcare Sector Value Stocks ↗
 
Via Benzinga
News headline image
Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
From Agile Therapeutics, Inc.
Via GlobeNewswire
News headline image
Agile Therapeutics (NASDAQ: AGRX) Upgraded To “Buy” Rating By Analysts At Maxim Group
Via ACCESSWIRE
News headline image
Agile Therapeutics (NASDAQ: AGRX) Upgraded To "Buy" Rating By Analysts At Maxim Group ↗
Maxim Group, a major investment bank, conducts and publishes stock analysis through its Equity Research team. The team has a strong reputation in the industry; a host of major firms use its research.... 
Via Benzinga
News headline image
5 Value Stocks To Watch In The Healthcare Sector ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Agile Therapeutics, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2023 ↗
 
Via Benzinga
News headline image
Agile Says It's On Track To Hit $25-$30 Million Net Annual Revenue After A Strong Performance In Its Second Quarter
Via ACCESSWIRE
News headline image
Agile Says It's On Track To Hit $25-$30 Million Net Annual Revenue After A Strong Performance In Its Second Quarter ↗
On August 9, Agile Therapeutics (NASDAQ: AGRX) released its second-quarter financial results, showing significant growth in revenue from its innovative weekly bi 
Via Benzinga
News headline image
A Look Into Healthcare Sector Value Stocks ↗
 
Via Benzinga
News headline image
Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Agile Therapeutics, Inc.
Via GlobeNewswire
News headline image
Agile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023
Live Conference Call and Webcast at 8:30 a.m. ET 
From Agile Therapeutics, Inc.
Via GlobeNewswire
News headline image
This Reproductive Health Company's Weekly Contraceptive Patch Can Reach Millions of Women Thanks to a Partnership With Afaxys
Via ACCESSWIRE
News headline image
Agile Therapeutics Partners With Telehealth Platforms To Expand Access To Weekly Birth Control Patch To Millions Of Women
Via ACCESSWIRE
News headline image
This Reproductive Health Company's Weekly Contraceptive Patch Can Reach Millions Of Women Thanks To A Partnership With Afaxys ↗
Agile Therapeutics, Inc.’s (NASDAQ: AGRX) partnership with Afaxys Pharma is expected to play a key role in propelling the women’ 
Via Benzinga
News headline image
Agile Therapeutics Partners With Telehealth Platforms To Expand Access To Weekly Birth Control Patch To Millions Of Women ↗
This month, Agile Therapeutics, Inc. (NASDAQ: AGRX) announced partnerships with FPA Women’s Health and 
Via Benzinga
News headline image
Agile Sees Renewed Hope For Even Broader Adoption Of Its Weekly Birth Control Patch After Biden’s Latest Executive Order Expanding Contraceptive Coverage
Via ACCESSWIRE
News headline image
Agile Sees Renewed Hope For Even Broader Adoption Of Its Weekly Birth Control Patch After Biden's Latest Executive Order Expanding Contraceptive Coverage ↗
In June, President Biden issued an Executive Order on Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services. 
Via Benzinga
News headline image
H.C. Wainwright Reiterates Buy Rating For Agile Therapeutics (NASDAQ: AGRX), Citing Growing Demand For Twirla, A Weekly Low Dose Birth Control Patch
Via ACCESSWIRE
News headline image
This Women's Healthcare Company Raised $7.5 Million In A Public Offering And Says It's Targeting $25 To $30 Million Net Revenue By End Of 2023
Via ACCESSWIRE
News headline image
Why Tattooed Chef Are Trading Lower By 47%; Here Are 20 Stocks Moving Premarket ↗
Gainers Micromobility.com Inc. (NASDAQ: MCOM) shares surged 60% to $0.18 in pre-market trading. micromobility.com recently reported a strategic realignment to strengthen its financial position and... 
Via Benzinga
News headline image
Agile Therapeutics Expects Its Innovative Once-A-Week Birth Control Patch To Drive Revenues Of $25-30 Million In 2023 - What Is The Hype All About?
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.